This company has been acquired
Acelyrin (SLRN) Stock Overview
A clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. More details
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
SLRN Community Fair Values
Create NarrativeSee what others think this stock is worth. Follow their fair value or set your own to get alerts.
Acelyrin, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.27 |
| 52 Week High | US$7.25 |
| 52 Week Low | US$1.85 |
| Beta | 1.09 |
| 1 Month Change | 0.89% |
| 3 Month Change | -12.69% |
| 1 Year Change | -45.04% |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | -90.34% |
Recent News & Updates
Recent updates
Acelyrin: Potential Buyout Led By Concentra Biosciences
Mar 12Acelyrin: Abandoned Programs Do Not Give Confidence
Dec 09Acelyrin: Straight Move To Phase 3 TED Studies Makes It Must Watch
Sep 20Companies Like Acelyrin (NASDAQ:SLRN) Are In A Position To Invest In Growth
Aug 03
Acelyrin: Analyzing Its Recovery And Potential In Psoriatic Arthritis
Mar 13Shareholder Returns
| SLRN | US Biotechs | US Market | |
|---|---|---|---|
| 7D | 0.9% | -1.4% | 0.2% |
| 1Y | -45.0% | 27.9% | 16.9% |
Return vs Industry: SLRN underperformed the US Biotechs industry which returned -13% over the past year.
Return vs Market: SLRN underperformed the US Market which returned 10.5% over the past year.
Price Volatility
| SLRN volatility | |
|---|---|
| SLRN Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 11.3% |
| Market Average Movement | 6.5% |
| 10% most volatile stocks in US Market | 16.5% |
| 10% least volatile stocks in US Market | 3.0% |
Stable Share Price: SLRN has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: SLRN's weekly volatility (10%) has been stable over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2020 | 83 | Mina Kim | www.acelyrin.com |
Acelyrin, Inc., a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company’s lead product candidate is lonigutamab, a subcutaneously delivered monoclonal antibody targeting IGF-1R, which has completed Phase 2 clinical trial for the treatment of Thyroid Eye Disease (TED). Acelyrin, Inc. was incorporated in 2020 and is headquartered in Agoura Hills, California.
Acelyrin, Inc. Fundamentals Summary
| SLRN fundamental statistics | |
|---|---|
| Market cap | US$229.16m |
| Earnings (TTM) | -US$268.52m |
| Revenue (TTM) | n/a |
Is SLRN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| SLRN income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$268.52m |
| Earnings | -US$268.52m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.66 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did SLRN perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/23 04:23 |
| End of Day Share Price | 2025/05/20 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Acelyrin, Inc. is covered by 2 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Akash Tewari | Jefferies LLC |
| Tyler Van Buren | TD Cowen |